Inhibrx Biosciences, Inc.
NASDAQ:INBXBiotechnology
-$2.58 today
- Market cap
- $1.02B
- Beta
- 3.32
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$8.35
Volume 0.29M
Average 0.43M
INBX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Inhibrx Biosciences, Inc.NASDAQ: INBX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 25.3% from a year ago
Cash & equivalents stood at $161.66M at the end of Q1 FY2026, down 25.3% from a year earlier and up 30.1% from the prior quarter. Over 3 fiscal years it compounded at -23.2% a year.
Context
- Cash & equivalents amounted to 87.9% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -25.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 124.22M USD
- Year-over-year change
- -18.6%
- 4-year CAGR
- -1.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 124.22M | -18.6% |
| FY2024 | 2024-12-31 | 152.6M | -45.1% |
| FY2023 | 2023-12-31 | 277.92M | +1.5% |
| FY2022 | 2022-12-31 | 273.87M | +108.6% |
| FY2021 | 2021-12-31 | 131.3M | — |
Cash & Equivalents vs competitors
How INBX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -25.3% is the 4th highest of 6, against a peer median of -25.2%.
- Cash & equivalents amounts to 87.9% of total assets for INBX, versus a peer median of 15.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | €301.65M EUR | +24.2% | +32.5% | 55.5% | |
TECXTectonic Therapeutic, Inc. | Mar 2026 | $236.89M USD | -22.6% | +91.8% | 96.1% |
| Mar 2026 | $161.66M USD | -25.3% | -23.2% | 87.9% | |
GENBGenerate Biomedicines, Inc. | Mar 2026 | $160.58M USD | — | — | 25.7% |
| Mar 2026 | $51.83M USD | -29.7% | +0.6% | 5.0% | |
| Sep 2026 | $26.95M USD | -25.2% | -0.6% | 3.7% | |
| Mar 2026 | $8.63M USD | -81.6% | -30.6% | 4.4% | |
| Peer median (excluding INBX) | — | -25.2% | +0.6% | 15.4% | |
Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 131.3M | 273.87M | 277.92M | 152.6M | 124.22M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 878K | 257K | 778K | 420K | 177K |
| Inventory | (878K) | 0 | 0 | 0 | 0 |
| Other Current Assets | 7.81M | 181K | 728K | 816K | 238K |
| Total Current Assets | 139.11M | 280.49M | 295.36M | 160.4M | 132.83M |
| Property, Plant & Equipment (Net) | 9.49M | 7.22M | 9.37M | 13.54M | 9.27M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.85M | 3.16M | 3.16M | 6.83M | 4.38M |
| Total Non-current Assets | 11.34M | 10.38M | 12.54M | 20.37M | 13.65M |
| Total Assets | 150.45M | 290.88M | 307.89M | 180.77M | 146.48M |
| Account Payables | 9.13M | 8.33M | 10.95M | 9.25M | 5.94M |
| Short-term Debt | 1.67M | 1.86M | 0 | 1.6M | 2.33M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.03M | 166K | 0 | 0 | 0 |
| Other Current Liabilities | 9.62M | 13.85M | 6.51M | 7.73M | 18.08M |
| Total Current Liabilities | 22.45M | 27.58M | 56.31M | 40.73M | 33.8M |
| Long-term Debt | 70.47M | 202.07M | 206.97M | 0 | 100.56M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 110K | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 5.03M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 75.61M | 205.24M | 208.08M | 6.45M | 104.69M |
| Total Liabilities | 98.07M | 232.82M | 264.39M | 47.18M | 138.49M |
| Common Stock | 4K | 4K | 5K | 1K | 1K |
| Retained Earnings | (227.15M) | (372.37M) | (613.73M) | (106.13M) | (246.19M) |
| Accumulated OCI | (150.45M) | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 279.53M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 52.38M | 58.06M | 43.5M | 133.58M | 7.99M |
| Total Debt | 72.14M | 207.1M | 210.14M | 8.05M | 107.01M |
| Net Debt | (59.16M) | (66.76M) | (67.78M) | (144.55M) | (17.21M) |
Inhibrx Biosciences, Inc.
NASDAQ:INBX
Intrinsic Alpha fair value
Locked
Current Price
$69.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.